1 results match your criteria: "Arthritis Bone Metabolism at Novartis Institute for Biomedical Research[Affiliation]"
Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
Br J Pharmacol
February 2005
Arthritis Bone Metabolism at Novartis Institute for Biomedical Research, East Hanover, NJ, USA.
1. This manuscript presents the preclinical profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor. 2.
View Article and Find Full Text PDF